ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2026
LGALS9 Is Beneficial to the Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation on Ischemic Stroke.
Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to investigate whether LGALS9 contributes to the effects of repetitive transcranial magnetic stimulation (rTMS) in the treatment of ischemic stroke (IS) in rats. Methods: The model of cerebral ischemia in rats was established via middle cerebral artery occlusion (MCAO). After being injected with LGALS9 siRNA prior to MCAO surgery and undergoing rTMS intervention postoperatively, the rats were evaluated for neurological function using the modified neurological severity score (mNSS) and for behavioral function through the foot-fault test and Rotarod test. Brain tissues were collected, and pathological changes were observed. Levels of IL-1β, IL-6, and IL-18 were assessed using ELISA. Immunohistochemistry was employed to detect CD86 expression, while RT-qPCR and Western blot were used to detect LGALS9 expression. Results: MCAO rats showed higher mNSS scores, more foot-fault errors, shorter Rotarod duration, elevated IL-6, IL-18, and IL-1β levels, decreased LGALS9 expression, increased CD86 expression, severe brain damage with increased apoptotic neurons, and elevated neuropathological injury scores. rTMS intervention improved the neurological function of MCAO rats and alleviated the inflammatory response in brain tissues, and LGALS9 enhanced the improvement effects induced by the rTMS intervention. Conclusion: rTMS can improve neurological function, reduce inflammatory responses, and protect brain tissue in rats with IS, effects for which LGALS9 is required to achieve the full benefit. The molecular mechanisms of the rTMS‑LGALS9 pathway remain unclear, as its downstream signaling and effects on neurological function and inflammation are not fully elucidated. Moreover, findings from animal models require further validation for human disease relevance and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.